Injection force of reusable insulin pens: Novopen 4, Lilly Luxura, Berlipen, and ClikSTAR

Journal of Diabetes Science and Technology

Volumn 5, Issue 5, 2011, Pages 1185-1190

  Friedrichs, Arnd ^a   Korger, Volker ^b   Adler, Steffen ^a  

^a LWS Risk Management Consult GmbH   (Germany)

^b Sanofi Deutschland GmbH   (Germany)

Author keywords

Berlipen; ClikSTAR; Injection force; Insulin pens; Lilly Luxura; Novopen 4

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ARTICLE; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; HUMAN; INSTRUMENTATION; SUBCUTANEOUS DRUG ADMINISTRATION;

DIABETES MELLITUS; DRUG DELIVERY SYSTEMS; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN;

EID: 84857419682     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681100500523     Document Type: Article

References (25)

1. Perfetti R. Reusable and disposable insulin pens for the treatment of diabetes: understanding the global diferences in user preference and an evaluation of inpatient insulin pen use. Diabetes Technol Ther. 2010;12 Suppl 1:S79-85.
2. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006;28(10):1712-25.
3. Goldstein HH. Pen devices to improve patient adherence with insulin therapy in type 2 diabetes. Postgrad Med. 2008;120(3):172-9.
4. Asche CV, Shane-McWhorter L, Raparla S. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence. Diabetes Technol Ther. 2010;12 Suppl 1:S101-8.
5. Baser O, Bouchard J, DeLuzio T, Henk H, Aagren M. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe. Adv Ther. 2010;27(2):94-104.
6. Fischer JS, Edelman SV, Schwartz SL. United States patient preference and usability for the new disposable insulin device Solostar versus other disposable pens. J Diabetes Sci Technol. 2008;2(6):1157-60.
7. Ignaut DA, Schwartz SL, Sarwat S, Murphy HL. Comparative device assessments: Humalog KwikPen compared with vial and syringe and FlexPen. Diabetes Educ. 2009;35(5):789-98.
8. Korytkowski M, Bell D, Jacobsen C, Suwannasari R; FlexPen Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, eficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25(11):2836-48.
9. Rakel RE. Improving patient acceptance and adherence in diabetes management: a focus on insulin therapy. Adv Ther. 2009;26(9):838-46.
10. Asakura T, Seino H, Kageyama M, Yohkoh N. Dosing accuracy of two insulin pre-filled pens. Curr Med Res Opin. 2008;24(5):1429-34.
11. Asakura T, Jensen KH. Comparison of intuitiveness, ease of use, and preference in two insulin pens. J Diabetes Sci Technol. 2009;3(2):312-19.
12. Krzywon M, Abdel-Tawab M, van der Burg T, Fuhr U, Schubert-Zsilavecz M. Dosing accuracy of commonly used disposable insulin pens. Curr Med Res Opin. 2010;26(4):901-5.
13. Weise A, Pfützner JW, Borig J, Pfützner AM, Safinowski M, Hänel H, Musholt PB, Pfützner A. Comparison of the dose accuracy of prefilled insulin pens. J Diabetes Sci Technol. 2009;3(1):149-53.
14. Bode A. Development of the SoloSTAR insulin pen device: design verification and validation. Expert Opin Drug Deliv. 2009;6(1):103-12.
15. Martin JM, Llewelyn JA, Ristic S, Bates PC. Acceptability and safety of a new 3.0 ml re-usable insulin pen (HumaPen) in clinical use. Diabetes Nutr Metab. 1999;12(5):306-9.
16. Pfützner A, Asakura T, Sommavilla B, Lee W. Insulin delivery with FlexPen: dose accuracy, patient preference and adherence. Expert Opin Drug Deliv. 2008;5(8):915-25.
17. Papanas N, Maltezos E. The diabetic hand: a forgotten complication? J Diabetes Complications. 2010;24(3):154-62.
18. Redmond CL, Bain GI, Laslett LL, McNeil JD. Hand syndromes associated with diabetes: impairments and obesity predict disability. J Rheumatol. 2009;36(12):2766-71.
19. Rosenbloom AL. Limitation of finger joint mobility in diabetes mellitus. J Diabet Complications. 1989;3(2):77-87.
20. Savaş S, Köroǧlu BK, Koyuncuoǧlu HR, Uzar E, Celik H, Tamer NM. The efects of the diabetes related soft tissue hand lesions and the reduced hand strength on functional disability of hand in type 2 diabetic patients. Diabetes Res Clin Pract. 2007;77(1):77-83.
21. Penfornis A. Performance of a new reusable insulin pen. Diabetes Technol Ther. 2011;13(3):373-9.
22. Rissler J, Jørgensen C, Rye Hansen M, Hansen NA. Evaluation of the injection force dynamics of a modified prefilled insulin pen. Expert Opin Pharmacother. 2008;9(13):2217-22.
23. Owen Mumford. Autopen®. http://www.owenmumford.com/en/range/6/ autopen.html. Accessed February 15, 2011.
24. Asakura T, Seino H, Jensen KH. Patient acceptance and issues of education of two durable insulin pen devices. Diabetes Technol Ther. 2008;10(4):299-304.
25. Clarke A, Spollett G. Dose accuracy and injection force dynamics of a novel disposable insulin pen. Expert Opin Drug Deliv. 2007;4(2):165-74.